Fibroheal Woundcare, a pioneering startup specializing in silk protein-based medical devices, has successfully raised Rs 6.3 crore in a pre-Series A funding round.
This investment round saw participation from a diverse group of investors, including surgeons, medical professionals, and bankers. In addition to the Rs 6.3 crore, Fibroheal has secured an additional commitment of Rs 10 crore, further strengthening its financial position.
Founded in 2017 by Vivek Mishra and Bharat Tandon, Fibroheal has been making significant strides in the medical device sector, particularly in the field of wound care. The startup’s products are already in use across over 500 hospitals in India and are available in more than 19 states. Furthermore, Fibroheal has expanded its reach by offering its products through various e-commerce platforms, making it easier for healthcare professionals and patients to access high-quality wound care solutions.
Fibroheal Woundcare plans to utilize the funds raised in this round to accelerate its go-to-market strategy, expand its product pipeline, and hire additional talent to support its growing operations. With an ambitious vision to revolutionize wound care, the company is focused on improving the healing process for patients suffering from a wide variety of acute, chronic, and traumatic wounds.
“Wound care is a critical area of healthcare that often gets overlooked, despite its profound impact on patients’ quality of life. With this funding, we aim to increase our market reach and enhance our product offerings,” said Vivek Mishra, Co-founder of Fibroheal. “We’re committed to providing cutting-edge solutions that improve healing outcomes for patients and help healthcare providers deliver better care.”
Fibroheal’s core innovation lies in its use of silk proteins for wound healing, which are known for their biocompatibility and regenerative properties. The company’s product range includes foams, mesh, and powders, designed to treat a wide variety of wounds, including post-operative wounds, bed sores, chronic ulcers, traumatic injuries, and infected C-section wounds. These products are specifically formulated to help heal non-healing or difficult-to-heal wounds that require advanced medical intervention.
The use of silk proteins in medical devices is gaining traction due to their natural healing properties, including antimicrobial activity, promoting cell growth, and supporting tissue regeneration. Fibroheal’s products are designed to accelerate the healing process, reduce infection risks, and improve overall wound management.
Fibroheal has already established a strong presence in the Indian healthcare market. Its products are currently used in more than 500 hospitals across India, serving both urban and rural areas. The company has made significant inroads into tier II and tier III cities, where access to advanced wound care solutions is often limited.
In addition to its hospital partnerships, Fibroheal is also leveraging the power of e-commerce to reach a wider audience. The company’s products are now available on leading online platforms, allowing healthcare professionals and consumers to access these advanced wound care solutions more conveniently.
“We’re seeing a strong demand for our products from hospitals, clinics, and consumers, especially as awareness about advanced wound care options grows. The expansion into e-commerce is a strategic move to ensure that our products are accessible to a larger audience,” said Bharat Tandon, Co-founder of Fibroheal.
With the funds raised in this round, Fibroheal plans to enhance its product offerings and expand its footprint across India and beyond. The company is particularly focused on improving its wound care products to address the evolving needs of patients and healthcare providers.
Fibroheal’s commitment to innovation is evident in its ongoing efforts to develop new and improved solutions for wound healing. By investing in research and development, the company aims to stay at the forefront of the wound care sector and continue to offer advanced, effective solutions for difficult-to-heal wounds.
The wound care market is growing rapidly, driven by increasing healthcare needs, an aging population, and rising awareness of advanced medical treatments. Fibroheal competes in this space with a variety of traditional and emerging players, but its unique focus on silk protein-based products sets it apart from many others. The biocompatible and regenerative nature of silk proteins has the potential to disrupt the wound care industry and improve patient outcomes significantly.
As Fibroheal continues to expand its product range and market presence, it is well-positioned to become a key player in the global wound care market, which is expected to see substantial growth in the coming years.
Fibroheal Woundcare’s successful funding round marks a significant milestone in the startup’s journey to revolutionize the wound care industry. With a unique product offering, strong growth potential, and a solid foundation in the Indian healthcare market, the company is poised to make a lasting impact on the global healthcare landscape.
The additional Rs 6.3 crore in funding, along with the Rs 10 crore commitment, will enable Fibroheal to ramp up its operations, accelerate product development, and expand its market presence. As the company continues to innovate and expand, it is set to provide advanced wound care solutions that improve the lives of patients and enhance the efficiency of healthcare providers.
By leveraging its expertise in silk protein technology, Fibroheal is not only setting new standards for wound healing but also paving the way for a future where patients have access to more effective, affordable, and accessible wound care options